Zobrazeno 1 - 10 of 61 pro vyhledávání: '"Iván Henríquez"'
1
Akademický článek
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Autor: Iván Henríquez, Mack Roach, Todd M. Morgan, Alberto Bossi, Junior A. Gómez, Oscar Abuchaibe, Felipe Couñago
Publikováno v: Biomedicines, Vol 9, Iss 9, p 1247 (2021)
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved d
Externí odkaz: https://doaj.org/article/e492b6eaec5844fb934c66f97ed63a8b
Zobrazit plný text záznamu
3
Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR)
Autor: P Samper, M M Flores, J Valero, R P de Celis, A. Conde, T Piquer, A Lozano, J. Jove, V Millan, P. Peleteiro, J.E. Baquedano, Julia Muñoz, I Villoslada, Iván Henríquez, P Diezhandino, A Illescas, M Eguiguren, C C Soler, E H Pardo
Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
The treatment of metastatic castration-resistant prostate cancer (mCRPC) has changed significantly in recent years. Inhibitors of androgen receptors have shown especially significant benefits in overall (OS) and progression-free survival (PFS), with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b5eb4aa5106e6e6d293fb2454d0591
https://doi.org/10.1007/s12094-019-02274-w
Zobrazit plný text záznamu
4
Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
Autor: Felipe Couñago, Daniel E. Spratt, Iván Henríquez, Alfonso Gomez-Iturriaga, Oscar Abuchaibe
Publikováno v: ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
World Journal of Clinical Oncology
Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (PSA) > 2 ng/mL, testosterone castration levels < 1.7 nm/L, and the absence of metastatic lesions on conventional imaging (computed tomography or bone
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c6e772e83ad0ca6852138acfecc819
http://hdl.handle.net/11268/11657
Zobrazit plný text záznamu
6
Clinical Applications of Molecular Biomarkers in Prostate Cancer
Autor: Daniel E. Spratt, E. Almagro, Fernando López-Campos, Rebeca Lozano, Ignacio Rodríguez-Melcón, Guillermo Velasco, Ana Aurora Díaz-Gavela, Luis Miguel Quintana Franco, Elia del Cerro, Felipe Couñago, José López-Torrecilla, Alfonso Gomez-Iturriaga, Estefanía Linares Espinós, Esaú Fenández-Pascual, Iván Henríquez, Juan Ignacio Martínez-Salamanca, Luis Leonardo Guerrero
Publikováno v: DDFV: Repositorio Institucional de la Universidad Francisco de Vitoria
Universidad Francisco de Vitoria
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Cancers, Vol 12, Iss 1550, p 1550 (2020)
Cancers
DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
instname
There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ec2eaa3c0d82484929164379c359014
http://hdl.handle.net/10641/2018
Zobrazit plný text záznamu
7
Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist
Autor: G. Sancho, Alfonso Gomez-Iturriaga, Manuel Recio, Iván Henríquez, Antonio Maldonado, Begoña Caballero, Fernando López-Campos, Antonio Gómez-Caamaño, Carlos Artigas, Elia del Cerro, Felipe Couñago
Publikováno v: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 37:302-314
Radiotherapy is a treatment with curative intent, both in patients with primary diagnosis of prostate cancer (PCa) and in patients presenting with biochemical recurrence after radical prostatectomy (RP). Moreover, the use of stereotactic body radioth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89107141a5cdefaae22b6f88aefeb84b
https://doi.org/10.1016/j.remnie.2018.07.010
Zobrazit plný text záznamu
8
Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy
Autor: David Parada, Oscar Abuchaibe, Meritxell Arenas, Iván Henríquez López, Arnau Besora, Laura Torres Royo, Pablo Gallardo, Marina Gascón, Karla B. Peña, Miquel Arquez Pianetta, Francesc Riu
Publikováno v: Reports of Practical Oncology & Radiotherapy. 22:251-257
Objectives Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::158d2e89977acf8783a17becda9b9ef6
https://doi.org/10.1016/j.rpor.2017.02.003
Zobrazit plný text záznamu
9
Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes
Autor: J. L. Mengual, José López-Torrecilla, C Vallejo, Alfonso Gomez-Iturriaga, Iván Henríquez, M.A. Cabeza, Antonio Gómez-Caamaño, M. Porras, E. Villafranca, J Pastor-Peidro, M L Vázquez, E. Collado, C González-San Segundo, J. Jove, M. Casaña, Juan Antonio Clemente, Almudena Zapatero, G Ossola, J.L. Muñoz-García
Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
INTRODUCTION: The clinical course in patients with prostate cancer (PCa) after biochemical failure (BF) has received limited attention. This study analyzes survival time from recurrence, patterns of progression, and the efficacy of salvage therapies
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0a07602399bb17af0debc5a86b10c89
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10661
Zobrazit plný text záznamu
10
Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database
Autor: M. Casaña, Juan Antonio Clemente, J. Pastor, Iván Henríquez, C. González, Víctor Méndez Muñoz, J. Muñoz, E. Collado, J. L. Mengual, Asunción Hervás, E. Villafranca, J. Jove, A. Gomez
Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
PurposeTo retrospectively assess outcomes and to identify prognostic factors in patients diagnosed with intermediate-risk (IR) prostate cancer (PCa) treated with primary external beam radiotherapy (EBRT).Materials and methodsData were obtained from t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d483fe8142eabfede841c3b47f9b8fa8
https://pubmed.ncbi.nlm.nih.gov/30536208
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje